Sign in|Join Free
About Us
Encyclopedia   /  Animal Pharmaceuticals  /  Immune Function Agents  /  Pharmaceutical Intermediates
Phentolamine structure

Phentolamine
  • CAS：50-60-2
  • MW:281.359
  • MF：C17H19N3O
Phentolamine is an α-adrenergicreceptor antagonist approved for use by the U.S.Food and Drug Administration (FDA) in 1952. Approved uses of phentolamine currently include (1) diagnosis of pheochromocytoma,(2) treatment of hypertension in pheochromocytoma, and (3) prevention of tissue necrosis after norepinephrine extravasation. Anearly use of injectable phentolamine involved the management of impotence (erectile dysfunction).Phentolamine is a short-acting, competitive antagonist at peripheral o-adrenergic receptors. It antagonizes both a and ozreceptors,thus blocking the actions of the circulating catecholamines epinephrine and norepinephrine. Phentolamine also stimulates β-adrenergic receptors in the heart and lungs. View more+
  Email   Tweet   Share
 
 
1. Names and Identifiers
1.1 Name
Phentolamine
1.2 Synonyms
2-((n-(m-hydroxyphenyl)-p-toluidino)methyl)-; 2-((n-(m-hydroxyphenyl)-p-toluidino)methyl)-2-imidazolin; 2-((n-(m-hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N-[m-Hydroxyphenyl]-p-toluidinomethyl)imidazoline; 3-[(4,5-Dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; 4-[(4,5-Dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol hydrochloride (1:1); AKOS NCG1-0052; AURORA KA-7803; Dibasin; EINECS 200-053-1; Fentolamin; Fentolamina; HYDROGEN 4-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)(4-METHYLPHENYL)AMINO]PHENOL CHLORIDE; LUN42518 HCl 47142-51-8(free base); m-[N-[2-Imidazolin-2-ylmethyl]-p-toluidino] phenol; MFCD00242985; Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-; Phenol, 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]-; Phenol, 4-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]-, hydrochloride (1:1); Phenotolamine; Phentalamine; Phentolamine hydrochloride; Phentolamine mesylas; Phentolamine?Mono-hydrochloride; PhentolamineMesilateBase; Phentolaminum; Regitin; Regitine; Rogitine;
View all
1.3 CAS No.
50-60-2
1.4 CID
5775
1.5 EINECS
200-053-1
1.6 Molecular Formula
C17H19N3O
1.7 Inchi
InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
1.8 InChkey
MRBDMNSDAVCSSF-UHFFFAOYSA-N
1.9 Canonical Smiles
CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
1.10 Isomers Smiles
CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
2. Properties
2.1 Appearance
WHITE POWDER
2.2 Color/Form
CRYSTALS
2.3 Physical
Solid
2.4 pKa
pKa 7.7 (Uncertain)
2.5 Water Solubility
Soluble Appearance:white crystalline powder
Transport Information:HAZARD
Hazard Symbols:UN NO.
particular:particular
View all
2.6 Stability
Following reconstitution of the commercially available lyophilized powder with sterile water; for injection to a concentration of 5 mg/mL, phentolamine mesylate; injection is stable for 48 hours at room temperature or 1 week at 2-8 deg C; however, the manufacturer recommends that the reconstituted injection be used immediately and not stored.
View all
3. Use and Manufacturing
3.1 Definition
ChEBI: A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used fo the treatment of hypertension.
3.2 Description
ChEBI: A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used fo the treatment of hypertension.
3.3 Methods of Manufacturing
m-(p-Toluidino)phenol; is refluxed with 2-chloromethylimidazoline hydrochloride and the resulting phentolamine; base treated with an equimolar protion of methanesulfonic acid;. /Phentolamine mesylate;/
3.4 Usage
Phentolamine is a synthetic imidazoline with alpha-adrenergic antagonist activity. As a competitive alpha-adrenergic antagonist, phentolamine binds to alpha-1 and alpha-2 receptors, resulting in a decrease in peripheral vascular resistance and vasodilatation. This agent also may block 5-hydroxytryptamine (5-HT) receptors and stimulate release of histamine from mast cells.Phentolamine is used mainly in the diagnosis of pheochromocytoma and to control or prevent paroxysmal hypertension immediately prior to or during pheochromocytomectomy.Phentolamine has been used to treat hypertensive crises secondary to MAO inhibitor/sympathomimetic amine interactions and rebound hypertension on withdrawal of clonidine, propranolol or other antihypertensive agents.
View all
4. Safety and Handling
4.1 Safety Profile
Poison by subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by ingestion. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx.
4.2 Formulations/Preparations
PHENTOLAMINE MESYLATE, USP (REGITINE MESYLATE), IS MARKETED FOR PARENTERAL USE IN STERILE AMPULS CONTAINING 5 MG. ... PHENTOLAMINE HYDROCHLORIDE, NF (REGITINE), IS AVAIL FOR ORAL USE IN TABLETS CONTAINING 50 MG.
4.3 Safety

Poison by subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by ingestion. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx. See also AMINES.

4.4 Toxicity
1.    

orl-rat LD50:1250 mg/kg

     PSEBAA    Proceedings of the Society for Experimental Biology and Medicine. 71 (1949),70.
2.    

scu-rat LD50:275 mg/kg

     PSEBAA    Proceedings of the Society for Experimental Biology and Medicine. 71 (1949),70.
3.    

ivn-rat LD50:75 mg/kg

     PSEBAA    Proceedings of the Society for Experimental Biology and Medicine. 71 (1949),70.
4.    

orl-mus LD50:1000 mg/kg

     AIPTAK    Archives Internationales de Pharmacodynamie et de Therapie. 112 (1957),319.
5.    

ipr-mus LD50:200 mg/kg

     ARZNAD    Arzneimittel-Forschung. Drug Research. 21 (1971),1727.
6.    

ivn-mus LD50:35 mg/kg

     AIPTAK    Archives Internationales de Pharmacodynamie et de Therapie. 105 (1956),317.
7.    

orl-rbt LD50:2000 mg/kg

     CLDND*    Compilation of LD50 Values of New Drugs. 81 (1951),352.
8.    

scu-rbt LDLo:200 mg/kg

     SMWOAS    Schweizerische Medizinische Wochenschrift. 81 (1951),352.
9.    

ivn-rbt LD50:28 mg/kg

     AIPTAK    Archives Internationales de Pharmacodynamie et de Therapie. 174 (1968),243.
View all
5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

no data available

2.2 GHS label elements, including precautionary statements

Pictogram(s) no data available
Signal word

no data available

Hazard statement(s)

no data available
Precautionary statement(s)
Prevention

no data available

Response

no data available

Storage

no data available

Disposal

no data available

2.3 Other hazards which do not result in classification

no data available

View all
6. NMR Spectrum
13C NMR : Predict  
1H NMR : Predict  
7. Synthesis Route
50-60-2Total: 2 Synthesis Route
 
107-15-3
107-15-3
 
50-60-2
50-60-2 49 Suppliers
 
61537-49-3
61537-49-3 33 Suppliers
 
13338-49-3
13338-49-3 60 Suppliers
 
50-60-2
50-60-2 49 Suppliers
8. Precursor and Product
precursor:
61537-49-3
61537-49-3
13338-49-3
13338-49-3
9. Computed Properties
  • Molecular Weight：281.359g/mol
  • Molecular Formula：C17H19N3O
  • Compound Is Canonicalized：True
  • Exact Mass：2.6
  • XLogP3-AA：281.152812238
  • Monoisotopic Mass：281.152812238
  • Complexity：363
  • Rotatable Bond Count：4
  • Hydrogen Bond Donor Count：2
  • Hydrogen Bond Acceptor Count：3
  • Topological Polar Surface Area：47.9
  • Heavy Atom Count：：21
  • Defined Atom Stereocenter Count：0
  • Undefined Atom Stereocenter Count：0
  • Defined Bond Stereocenter Count：0
  • Undefined Bond Stereocenter Count：0
  • Isotope Atom Count：0
  • Covalently-Bonded Unit Count：1
  • CACTVS Substructure Key Fingerprint：AAADceB7IAAAAAAAAAAAAAAAAAAAAQAAAAAwYAAAAAAAAAABQAAAHgAQCAAADAzBmAQzxoPAAgCgAiZiZACCAAEhIgAJiIAebIgIZmLCmZOUcAhm0BnI2AeQ0AMOCAAAAgAAAAAQAAAEAAAAAAAAAAAAAA==
10.Other Information
description
Phentolamine is an α-adrenergicreceptor antagonist approved for use by the U.S.Food and Drug Administration (FDA) in 1952. Approved uses of phentolamine currently include (1) diagnosis of pheochromocytoma,(2) treatment of hypertension in pheochromocytoma, and (3) prevention of tissue necrosis after norepinephrine extravasation. Anearly use of injectable phentolamine involved the management of impotence (erectile dysfunction).
Phentolamine is a short-acting, competitive antagonist at peripheral o-adrenergic receptors. It antagonizes both a and ozreceptors,thus blocking the actions of the circulating catecholamines epinephrine and norepinephrine. Phentolamine also stimulates β-adrenergic receptors in the heart and lungs.
View all
Pharmacology
Analogues of the imidazoline adrenergic amines were among the first synthetic adrenergic blocking agents to be identified. Phentolamine is the only compound from this class that is still clinically available.
Phentolamine is a competitive non-selective α1- and α2-adrenergic receptor blocker of relatively short duration of action. It causes vasodilatation and a fall in blood pressure resulting from the blockade of both post-junctional vascular α1- and α2-adrenoceptors. It also antagonises the vasoconstrictor response to noradrenaline and adrenaline infusions. Enhanced neural release of noradrenaline due to presynaptic α2-blockade may contribute to the positive inotropic and chronotropic effects of Regitine on cardiac muscle.
View all
Uses
Phentolamine is a synthetic imidazoline with alpha-adrenergic antagonist activity. As a competitive alpha-adrenergic antagonist, phentolamine binds to alpha-1 and alpha-2 receptors, resulting in a decrease in peripheral vascular resistance and vasodilatation. This agent also may block 5-hydroxytryptamine (5-HT) receptors and stimulate release of histamine from mast cells.
Phentolamine is used mainly in the diagnosis of pheochromocytoma and to control or prevent paroxysmal hypertension immediately prior to or during pheochromocytomectomy.
Phentolamine has been used to treat hypertensive crises secondary to MAO inhibitor/sympathomimetic amine interactions and rebound hypertension on withdrawal of clonidine, propranolol or other antihypertensive agents.
View all
clinical use
The clinical effects of phentolamine include peripheral vasodilation and tachycardia.Vasodilation results from both direct relaxation of vascular smooth muscle and a blockade. The drug produces positive inotropic and chronotropic effects,leading to an increase in cardiac output.In smaller doses, the positive inotropic effect can predominate and raise blood pressure; in larger doses, peripheral vasodilation can mask the inotropic effect and lower blood pressure.These actions make phentolamine useful in treating hypertension caused by increased circulating levels of epinephrine and norepinephrine, as occurs in pheochromocytoma.
The effects of phentolamine in treating impotence are mediated by α-adrenergic blockade in penile blood vessels. Actions of the drug cause relaxation of the trabecular cavernous smooth muscles and dilation of the penile arteries; this increases arterial blood flow into the corpus cavernosa and subsequently causes an erection. Phentolamine is administered IV or IM but can be injected subcutaneously to prevent local tissue necrosis when vasoconstrictor drugs extravasate. The pharmacokinetics of phentolamine is largely unknown;10% of a parenteral dose is excreted in the urine unchanged.
View all
Carcinogenicity / mutagenicity
Experimental data have established that phentolamine lacks mutagenic potential in bacteria, and does not induce chromosomal aberrations in mammalian somatic cells in vivo. Long-term carcinogenicity studies have not been conducted with phentolamine.
Overdosage
No deaths due to acute poisoning with phentolamine have been reported.
Overdosage with parenterally administered phentolamine is characterized chiefly by cardiovascular disturbances, such as arrhythmias, tachycardia, hypotension, and possibly shock. In addition, the following might occur: excitation, headache, sweating, pupillary contraction, visual disturbances, nausea, vomiting, diarrhea, or hypoglycemia.
There is no specific antidote; treatment consists of appropriate monitoring and supportive care. Substantial decreases in blood pressure or other evidence of shock-like conditions should be treated vigorously and promptly.
View all
Description
Phentolamine is also a derivative of imidazoline that exhibits a direct α-adrenoblocking, muscle-relaxant effect on smooth muscle as well as cholinomimetic, histamine, and sympathomimetic effects. The chemical variation of its structure permits a few of its properties to be more expressed. For example, the aforementioned tolazoline, 2-benzyl-2-imidazoline, a structural analog of phentolamine, has more of an expressed muscle-relaxant effect on smooth muscle than an α-adrenoblocking effect.
View all
Originator
Regitine, Ciba, US ,1952
Uses
Phentolamine is used for peripheral blood circulation disorders, in particular in the beginning stages of gangrene, for treatment of trophic ulcers of the extremities, bedsores, and frostbite.
Uses
Anti-adrenergic.
Phentolamine is used to prevent or control hypertensive episodes that occurin patients with pheochromocytoma. It also has been used incombination with papaverine to treat impotence.
Definition
ChEBI: A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used fo the treatment of hypertension.
Indications
Human erectile tissue has a population of membrane receptors that are predominantly of the -adrenoceptor subtype. Phentolamine (Vasomax) is a nonselective - adrenoceptor blocking agent (see Chapter 11), and like other such agents, it has been used to treat ED. Nonselective adrenoceptor antagonists may provoke a reflex that increases both sympathetic outflow and the release of norepinephrine.
View all
Manufacturing Process
199.24 parts of N-(p-methylphenyl)-m'-hydroxyphenylamine and 77.52 parts of 2-chloromethylimidazoline hydrochloride are heated for sixteen hours in an oil bath having a temperature of 150°C, while stirring and introducing a current of nitrogen. The viscous contents of the flask are then cooled to about 100°C, mixed with 400 parts by volume of hot water, and stirred for a short time.
After further cooling to about 60°C, 200 parts by volume of water and 500 parts by volume of ethyl acetate at 60°C are added, and the aqueous layer is separated. The excess of starting material may be recovered from the ethyl acetate.
The aqueous portion is chilled in a cooling chamber at -10°C, whereupon the hydrochloride of 2-[N-(p-methylphenyl)-N-(m'-hydroxyphenyl)-aminomethyl]imidazoline crystallizes. Upon being concentrated and cooled the mother liquor yields a further quantity of the hydrochloride. The combined quantities of hydrochloride are treated with a small quantity of cold water, dried with care, and washed with ethyl acetate. The product is then crystallized from a mixture of alcohol and ethyl acetate, and there is obtained a hydrochloride melting at 239°-240°C.
View all
Brand name
Regitine (Novartis) [Name previously used: Phentolamine Methanesulfonate.].
Therapeutic Function
Adrenergic blocker
General Description
Phentolamine isthe more effectiveα -blocker.
Mechanism of action
Its mechanism of action is as an α-adrenergic antagonist of both α1- and α2-receptors, causing vasodilation and reduction in peripheral resistance. When administered by intracavernosal injection, it is thought to cause relaxation of the cavernous smooth muscles and vasodilation of the penile arteries. This results in increased arterial blood flow into the corpus cavernosa as well as swelling and elongation of the penis. Venous outflow also is reduced, possibly as a result of increased venous resistance. Phentolamine is slowly released into venous circulation with minimal, if any, systemic effects. Time to peak effect is within 10 minutes, and duration of action when used with papaverine is 1 to 6 hours.
View all
Clinical Use
Phentolamine has been used orally and intracavernosally in the treatment of ED. Following oral administration, phentolamine has a plasma half-life of about 30 minutes and a duration of action of 2 to 4 hours. An intracavernosal injection of phentolamine results in the drug reaching maximum serum levels in about 20 to 30 minutes. It is rapidly metabolized. Phentolamine has been used in combination with papaverine, chlorpromazine, and vasoactive peptides in the treatment of ED.
View all
Side effects
Side effects of phentolamine are dose related. It may cause orthostatic hypotension, reflex tachycardia, cardiac arrhythmias, and rarely, myocardial infarction. Phentolamine also may reduce sperm motility in vitro.
Safety Profile
Poison by subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by ingestion. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx.
Chemical Synthesis
Phentolamine, 2-[[N-(3′-hydroxyphenyl)-para-toluidion]methyl]-2- imidazoline (12.2.8), is synthesized by alkylation of 3-(4-methylanilino)phenol using 2-chloromethylimidazoline [36, 37].

11. Toltal 37 Suppliers View more
Safe Delivery 99% Pure Phentolamine Powder CAS 50-60-2 Door To Door Fentolamina Em Po Polvo
Guangzhou Tengyue Chemical Co., Ltd.
 1YR   China
Tel: Update Time:2024/11/15
inquire
Phentolamine
Dayang Chem (Hangzhou) Co., Ltd.
 1YR   China
Tel: Update Time:2024/06/17
inquire
Phentolamine
Wuhan Fortuna Chemical Co., Ltd.
 1YR   China
Tel: Update Time:2024/08/08
inquire
Phentolamine
Wuhan Senwayer Century chemical Co.,Ltd
  China
Tel: Update Time:2020/06/28
inquire
High quality phentolamine CAS 50-60-2
Hebei LuXi Bio-Technology Co.,Ltd
  China
Tel: Update Time:2018/01/20
inquire
12. Related Questions
What is the pharmacological action of Phentolamine?Phentolamine has a vasodilatory effect and is commonly used in clinical practice for conditions such as vasospastic diseases, including acrocyanosis, Raynaud's disease, septic shock, and ventricular p..
What are the indications and side effects of Phentolamine? Phentolamine is an alpha-adrenoceptor blocker. It is clinically used for vasospasm diseases, such as acral arterial spasm (Raynaud's disease), acrocyanosis, infectious toxic shock, and diagnostic tes..
What are the pharmacological effects and clinical applications of Phentolamine? Phentolamine is used for vasospastic diseases, such as acral arterial spasm (Raynaud's disease), acrocyanosis, infectious toxic shock, and diagnostic tests for pheochromocytoma. It is also effective ..
13. Realated Product Infomation
 
1. Names and Identifiers
2. Properties
3. Use and Manufacturing
4. Safety and Handling
5. Msds
6. NMR Spectrum
7. Synthesis Route
8. Precursor and Product
9. Computational chemical data
10. Other Information
11. Toltal 37 Suppliers
12. Related Questions
13. Realated Product Infomation
 
 
Cancel
 
CAS Products Suppliers
Popular Searches
Request For Quotation